10-Q: Bone Biologics Reports Q1 2024 Results, Highlights Progress in NELL-1 Development

Bone Biologics Corporation reported its financial results for the first quarter of 2024, showing a significant decrease in research and development expenses and a net loss of $865,970.

Summary

• Bone Biologics Corporation reported a net loss of $865,970 for the first quarter of 2024, compared to a net loss of $3,709,899 for the same period in 2023.
• Research and development expenses decreased significantly to $245,625 from $2,590,645 year-over-year, primarily due to reduced NELL-1 protein production costs.
• General and administrative expenses increased to $657,911 from $556,892 year-over-year, mainly due to legal expenses related to settling litigation.
• The company completed a public offering on March 6, 2024, generating net proceeds of $1.5 million.
• As of March 31, 2024, the company had $3.2 million in cash, expected to fund operations through the third quarter of 2024.
• The company estimates operating expenditures for the next twelve months to be $6.9 million.
• The company is focused on developing NELL-1/DBM for bone regeneration in spinal fusion, which is classified as a device/drug combination product requiring FDA pre-market approval.
• The company has an exclusive license agreement with UCLA TDG for the NELL-1 technology, which includes milestone payments and royalties.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its net loss and secured some funding, the going concern warning and dependence on future capital raises are significant concerns. The company is still in a high-risk development phase.

Positives

• The company significantly reduced its net loss compared to the same quarter last year.
• Research and development expenses decreased substantially, indicating a shift in spending after initial clinical study preparations.
• The successful public offering in March 2024 provided a cash infusion of $1.5 million.
• The company has sufficient cash to fund operations through the third quarter of 2024.

Negatives

• The company continues to operate at a loss, with a net loss of $865,970 for the quarter.
• General and administrative expenses increased due to legal costs.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund future operations.
• The company is subject to significant regulatory hurdles and clinical trial risks.

Risks

• The company's ability to continue as a going concern is in doubt due to accumulated losses and the need for additional funding.
• There is no assurance that the company will be able to raise sufficient capital to fund its operations.
• The company's product development is subject to extensive regulatory requirements and clinical trial risks.
• The company is dependent on its exclusive license agreement with UCLA TDG, which includes milestone payments and royalties.
• The company faces the risk of not meeting diligence milestones under the UCLA TDG license agreement, which could lead to termination or reduction of the license.
• The company is subject to potential product liability and defect claims.
• The company is exposed to risks related to inflation, rising interest rates, and potential recession.

Future Outlook

The company anticipates continued substantial investment in development activities for NELL-1 as it prepares for its pivotal clinical study. The company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. The company expects available cash to fund operations through the third quarter of 2024.

Management Comments

• The company's CEO, Jeffrey Frelick, will continue to serve in his role with an annual base salary of $300,000 and the opportunity to earn an annual bonus targeted at 50% of his base salary.
• The company's CFO, Deina Walsh, is eligible to receive a transaction bonus of 0.5% to 1% of the transaction value depending on the size of the transaction in the event the company is acquired.

Industry Context

The company operates in the medical device industry, specifically focusing on bone regeneration in spinal fusion. This is a competitive market with established players and significant regulatory hurdles. The company's success depends on the successful development and commercialization of its NELL-1/DBM product, which is subject to FDA approval.

Comparison to Industry Standards

• The company's lack of revenue is typical for a development-stage medical device company.
• The significant decrease in research and development expenses suggests a shift from initial development to clinical trial preparation.
• The company's reliance on external funding is common in the biotech and medical device sectors.
• The company's cash burn rate and estimated future expenses are consistent with other companies in similar stages of development.
• The company's need to raise an estimated $29 million to achieve FDA approval is typical for a medical device company in the clinical trial phase.
• The company's exclusive license agreement with UCLA TDG is a common arrangement for companies developing university-based technologies.
• The company's milestone payments and royalty obligations to UCLA TDG are standard in such licensing agreements.
• The company's need to spend at least $1,000,000 per calendar year on pre-clinical or clinical development is a common requirement in licensing agreements.

Management Changes

Legal Proceedings

• The company entered into a Settlement Agreement and Mutual General Release with Drs. Bessie (Chia) Soo and Kang (Eric) Ting, settling claims for breach of contract and tortious interference with contract. The company paid $414,989 of the $750,000 settlement, with the remainder paid by its insurance carrier.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity financing.
• Employees are subject to the company's financial stability and ability to continue operations.
• Customers (potential future patients) are dependent on the successful development and approval of the company's products.
• Suppliers and creditors are exposed to the company's financial risks.

Next Steps

• The company will continue to develop its NELL-1/DBM product.
• The company will prepare for its pivotal clinical study.
• The company will attempt to raise additional debt and/or equity financing.
• The company will continue to monitor its compliance with Nasdaq listing requirements.

Key Dates

Keywords

NELL-1, bone regeneration, spinal fusion, medical device, clinical trials, FDA approval, public offering, UCLA TDG, warrants, stock options